Wall Street Zen lowered shares of Coherus Oncology (NASDAQ:CHRS – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.
CHRS has been the topic of a number of other research reports. HC Wainwright initiated coverage on Coherus Oncology in a research note on Thursday, October 29th. They set a “buy” rating on the stock. Weiss Ratings cut Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Coherus Oncology currently has an average rating of “Moderate Buy” and an average price target of $11.00.
View Our Latest Analysis on Coherus Oncology
Coherus Oncology Stock Performance
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The business had revenue of $14.27 million during the quarter, compared to analyst estimates of $15.90 million. Coherus Oncology had a negative net margin of 253.43% and a negative return on equity of 274.46%. On average, research analysts predict that Coherus Oncology will post -0.83 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in CHRS. Spark Investment Management LLC acquired a new position in Coherus Oncology in the second quarter valued at $25,000. Cetera Investment Advisers bought a new stake in Coherus Oncology during the first quarter valued at $54,000. Dimensional Fund Advisors LP bought a new stake in Coherus Oncology during the first quarter valued at $60,000. The Manufacturers Life Insurance Company acquired a new stake in Coherus Oncology during the 2nd quarter worth about $54,000. Finally, Hsbc Holdings PLC acquired a new stake in Coherus Oncology during the 2nd quarter worth about $131,000. 72.82% of the stock is owned by institutional investors.
About Coherus Oncology
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Further Reading
- Five stocks we like better than Coherus Oncology
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
